Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, S.
Right arrow Articles by Schlegel, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, S.
Right arrow Articles by Schlegel, U.
Neurology 1999;53:220
© 1999 American Academy of Neurology
Brief Communications

Lethal capillary leak syndrome after a single administration of interferon beta-1b

S. Schmidt, MD, H.-J. Hertfelder, MD, PhD, T. von Spiegel, MD, R. Hering, MD, M. Harzheim, MD, H. Lassmann, MD, M. Deckert-Schlüter, MD and U. Schlegel, MD

From the Department of Neurology (Drs. Schmidt, Harzheim, and Schlegel), Institute of Experimental Hematology and Transfusion Medicine (Dr. Hertfelder), Department of Anesthesiology (Drs. von Spiegel and Hering), Department of Neuropathology (Dr. Deckert-Schlüter), University of Bonn, Germany; and the Neurological Institute (Dr. Lassmann), University of Vienna, Austria.

Address correspondence and reprint requests to Dr. Uwe Schlegel, Department of Neurology, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany.

Interferon beta-1b (IFNß-1b) is a potent immunomodulatory drug in the treatment of MS. We report a lethal capillary leak syndrome after the administration of IFNß-1b in a patient with disseminated white matter disease, monoclonal gammopathy, and acquired C1 inhibitor (C1-INH) deficiency. IFNß-1b may cause a transient release of proinflammatory cytokines finally resulting in an uninhibited activation of the complement cascade in patients with C1-INH deficiency.




This article has been cited by other articles:


Home page
 Mult SclerHome page
S. Schmidt, T. Schneider, I. Schmidt-Wolf, Y. Ko, U. Schlegel, T. Klockgether, and H.-J. Hertfelder
Letter to the editor
Multiple Sclerosis, April 1, 2004; 10(2): 243 - 244.
[PDF]

Home page
 Nephrol Dial TransplantHome page
C. Vigneau, J.-P. Haymann, N. Khoury, J.-D. Sraer, and E. Rondeau
An unusual evolution of the systemic capillary leak syndrome
Nephrol. Dial. Transplant., March 1, 2002; 17(3): 492 - 494.
[Full Text] [PDF]

Home page
 NeurologyHome page
G. Niederwieser, S. Schmidt, and U. Schlegel
Lethal capillary leak syndrome after a single administration of interferon beta-1b
Neurology, April 11, 2000; 54(7): 1542 - 1546.
[Full Text] [PDF]

Home page
 NeurologyHome page
E. U. Walther and R. Hohlfeld
Multiple sclerosis: Side effects of interferon beta therapy and their management
Neurology, November 1, 1999; 53(8): 1622 - 1622.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.